Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” ...

Company Engaging with U.S. and EU Regulatory Authorities to Determine the Optimal Global Pivotal Phase 3 Program for ANX007 BRISBANE, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ...

Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 30, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc., a clinical-stage biopharmaceutical ...

Ocugen Inc. OCGN shares are down during Tuesday’s session following topline data from its Phase 2 ArMaDa trial of OCU410.

Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRISBANE, Calif., ...

Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures BRISBANE, Calif., ...